As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), combined with a standard-of-care regimen to treat adults with newly ...

Deal generates more cash for acquisitive French beauty group Sale price is a 2.8% discount to Sanofi’s Friday shares close. L’Oreal is selling 29.6 million shares at €101.50 each, the companies said ...

Sanofi’s Sarclisa has received approval in more than 50 nations for multiple indications. Credit: rafaelnlins/Shutterstock. Sanofi has received China’s National ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...